Current controversies in follicular lymphoma

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–18. Altieri, 2005, Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database, Blood, 106, 668, 10.1182/blood-2005-01-0140 Groves, 2000, Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995, J Natl Cancer Inst, 92, 1240, 10.1093/jnci/92.15.1240 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. prepublished online Sept. 8, 2005. Swenson, 2005, Improved survival of follicular lymphoma patients in the United States, J Clin Oncol, 23, 5019, 10.1200/JCO.2005.04.503 Horning, 1993, Natural history of and therapy for the indolent non-Hodgkin’s lymphomas, Semin Oncol, 20, 75 Vaux, 1988, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nature, 335, 440, 10.1038/335440a0 Graninger, 1987, Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells, J Clin Invest, 80, 1512, 10.1172/JCI113235 Yang, 1996, Molecular thanatopsis: a discourse on the BCL2 family and cell death, Blood, 88, 386, 10.1182/blood.V88.2.386.bloodjournal882386 Lopez-Guillermo, 1999, Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma, Blood, 93, 3081, 10.1182/blood.V93.9.3081 Nathwani, 2001, Follicular lymphoma, 162 Mann, 1983, Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method, Hematol Oncol, 1, 187, 10.1002/hon.2900010209 Hans, 2003, A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival, Blood, 101, 2363, 10.1182/blood-2002-07-2298 A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94. Lopez-Guillermo, 1994, Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma, J Clin Oncol, 12, 1343, 10.1200/JCO.1994.12.7.1343 Solal-Celigny, 2004, Follicular lymphoma international prognostic index, Blood, 104, 1258, 10.1182/blood-2003-12-4434 Ghielmini, 2005, Does the FLIPI apply to grade 3 follicular lymphoma?, Blood, 105, 4892, 10.1182/blood-2005-01-0053 Perea, 2005, Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems, Ann Oncol, 16, 1508, 10.1093/annonc/mdi269 Dave, 2004, Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells, N Engl J Med, 351, 2159, 10.1056/NEJMoa041869 Kuppers, 2004, Prognosis in follicular lymphoma–it’s in the microenvironment, N Engl J Med, 351, 2152, 10.1056/NEJMp048257 Farinha, 2005, Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL), Blood, 106, 2169, 10.1182/blood-2005-04-1565 Glas, 2005, Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment, Blood, 105, 301, 10.1182/blood-2004-06-2298 Anderson, 1982, Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute, Cancer, 50, 2699, 10.1002/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A Peterson, 2004, Long term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone, Journal of Clinical Oncology, 22, 563s Wilder, 2001, Long-term results with radiotherapy for Stage I-II follicular lymphomas, Int J Radiat Oncol Biol Phys, 51, 1219, 10.1016/S0360-3016(01)01747-3 Seymour, 2003, Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma, J Clin Oncol, 21, 2115, 10.1200/JCO.2003.07.111 Advani, 2004, Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy, J Clin Oncol, 22, 1454, 10.1200/JCO.2004.10.086 Young, 1988, The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment, Semin Hematol, 25, 11 Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte, J Clin Oncol, 15, 1110, 10.1200/JCO.1997.15.3.1110 Ardeshna, 2003, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, Lancet, 362, 516, 10.1016/S0140-6736(03)14110-4 Morrison, 1993, Combination chemotherapy in the treatment of follicular low-grade lymphoma, Leuk Lymphoma, 10, 29, 10.3109/10428199309149108 Hoppe, 1981, The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation, Blood, 58, 592, 10.1182/blood.V58.3.592.592 Peterson, 2003, Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B, J Clin Oncol, 21, 5, 10.1200/jco.2003.05.128 Longo, 1984, Prolonged initial remission in patients with nodular mixed lymphoma, Ann Intern Med, 100, 651, 10.7326/0003-4819-100-5-651 Glick, 1981, Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease- free survival with COPP chemotherapy, Blood, 58, 920, 10.1182/blood.V58.5.920.920 Hagenbeek, 2001, Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin’s lymphoma. Final analysis of a prospective randmoized phase III intergroup trial, Blood, 98, 843a Klasa, 2002, Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin’s lymphoma previously treated with an alkylating agent or alkylator-containing regimen, J Clin Oncol, 20, 4649, 10.1200/JCO.2002.11.068 Plunkett, 1993, Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies, Semin Oncol, 20, 2 Bellosillo, 1999, In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia, Blood, 94, 2836, 10.1182/blood.V94.8.2836.420k35_2836_2843 Kano, 2000, In vitro cytotoxic effects of fludarabine (2-F- ara-A) in combination with commonly used antileukemic agents by isobologram analysis, Leukemia, 14, 379, 10.1038/sj.leu.2401684 Johnston, 1994, Combination therapy with nucleoside analogs and alkylating agents, Leukemia, 8, S140 Hochster, 2000, Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up–a report from the Eastern Cooperative Oncology Group, J Clin Oncol, 18, 987, 10.1200/JCO.2000.18.5.987 Flinn, 2000, Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies, Blood, 96, 71, 10.1182/blood.V96.1.71 Hochster, 2004, Results of E1496: a phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma, J Clin Oncol, 22, 558, 10.1200/jco.2004.22.14_suppl.6502 McLaughlin, 1996, Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma, J Clin Oncol, 14, 1262, 10.1200/JCO.1996.14.4.1262 Zinzani, 2004, Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma, J Clin Oncol, 22, 2654, 10.1200/JCO.2004.07.170 Tournilhac, 2004, Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia, Blood, 103, 363, 10.1182/blood-2003-05-1449 McLaughlin, 2005, Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha, Blood, 105, 4573, 10.1182/blood-2004-08-3035 McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825 Foran, 2000, A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response, Br J Haematol, 109, 81, 10.1046/j.1365-2141.2000.01965.x Feuring-Buske, 2000, IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, Ann Hematol, 79, 493, 10.1007/s002770000163 Davis, 2000, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment, J Clin Oncol, 18, 3135, 10.1200/JCO.2000.18.17.3135 Witzig, 2005, Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group, J Clin Oncol, 23, 1103, 10.1200/JCO.2005.12.052 Colombat, 2001, Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, Blood, 97, 101, 10.1182/blood.V97.1.101 Solal-Celigny, 2002, Updated results of rituximab as single first-line therapy for patients with follicular lymphoma and a low tumor burden: clinical and molecular evaluation, Ann Oncol, 13, 143 Solal-Celigny, 2004, Single 4 dose rituximab treatment for low-tumor burden follicular lymphoma (FL): survival analyses with a follow-up of at least 5 years, Blood, 104, 169a, 10.1182/blood.V104.11.585.585 Hainsworth, 2005, Maximizing therapeutic benefit of rituximab: maintenance therapy versus re- treatment at progression in patients with indolent non-Hodgkin’s lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network, J Clin Oncol, 23, 1088, 10.1200/JCO.2005.12.191 Ghielmini, 2004, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, Blood, 103, 4416, 10.1182/blood-2003-10-3411 Colocci, 2005, Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance therapy, J Clin Oncol, 23, 566s, 10.1200/jco.2005.23.16_suppl.6526 Demidem, 1997, Chimeric anti- CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs, Cancer Biother Radiopharm, 12, 177, 10.1089/cbr.1997.12.177 Czuczman, 2004, Prolonged clinical and molecular remission in patients with low-grade or follicular non- Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up, J Clin Oncol, 22, 4711, 10.1200/JCO.2004.04.020 Hagenbeek, 2005, The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial, Ann Oncol, 16, v52 Forstpointner, 2004, The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, 104, 3064, 10.1182/blood-2004-04-1323 Hiddemann, 2005, Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol, 23, 566s, 10.1200/jco.2005.23.16_suppl.6527 Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 1417, 10.1182/blood-2004-08-3175 Herold, 2004, Results of a randomized open label phase II study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) with MCP alone in untreated advanced indolent non- Hodgkin’s lymphoma (NHL) and mantle-cell lymphoma, Blood, 104, 169a, 10.1182/blood.V104.11.584.584 Hiddemann, 2004, The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment remission in follicular lymphoma but not in mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), Blood, 104, 50a, 10.1182/blood.V104.11.161.161 Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood. prepublsihed online Aug. 25, 2005. Salles, 2004, Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL- 2000 randomized trial, Blood, 104, 49a, 10.1182/blood.V104.11.160.160 Habermann, 2004, Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update, Blood, 104, 40a Imrie, 2005, Rituximab plus CVP vs. CVP alone as first-line treatment for follicular lymphoma: treatment effect according to baseline prognostic factors, J Clin Oncol, 23, 566s, 10.1200/jco.2005.23.16_suppl.6525 Chanan-Khan, 2002, Radioimmunotherapy in non-Hodgkin lymphoma, Curr Opin Oncol, 14, 484, 10.1097/00001622-200209000-00003 Witzig, 2002, Randomized controlled trial of yttrium-90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma, J Clin Oncol, 20, 2453, 10.1200/JCO.2002.11.076 Gordon, 2004, Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma, Clin Lymphoma, 5, 98, 10.3816/CLM.2004.n.015 Witzig, 2002, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma, J Clin Oncol, 20, 3262, 10.1200/JCO.2002.11.017 Witzig, 2003, Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma, J Clin Oncol, 21, 1263, 10.1200/JCO.2003.08.043 Pedersen-Bjergaard, 1985, Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non- Hodgkin’s lymphomas. Comparison with results obtained in patients treated for Hodgkin’s disease and ovarian carcinoma with other alkylating agents, Ann Intern Med, 103, 195, 10.7326/0003-4819-103-2-195 Davies, 2005, A review of tositumomab and I (131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma, Expert Opin Biol Ther, 5, 577, 10.1517/14712598.5.4.577 Kaminski, 2001, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 19, 3918, 10.1200/JCO.2001.19.19.3918 Kaminski, 2005, 131I-tositumomab therapy as initial treatment for follicular lymphoma, N Engl J Med, 352, 441, 10.1056/NEJMoa041511 Connors, 2005, Radioimmunotherapy–hot new treatment for lymphoma, N Engl J Med, 352, 496, 10.1056/NEJMe048291 Press, 2003, A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911, Blood, 102, 1606, 10.1182/blood-2003-01-0287 Bennett, 2005, Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non- Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, 105, 4576, 10.1182/blood-2004-12-4690 Ansell, 2002, Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma, J Clin Oncol, 20, 3885, 10.1200/JCO.2002.10.143 Cooney, 2002, Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab, Bone Marrow Transplant, 29, 523, 10.1038/sj.bmt.1703398 Bendandi, 1999, Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma, Nat Med, 5, 1171, 10.1038/13928 Kunkel, 2004, Idiotype vaccines in the treatment of B-cell non-Hodgkin’s lymphoma, Cancer Invest, 22, 97, 10.1081/CNV-120027584 Hurvitz, 2005, Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId, Expert Opin Biol Ther, 5, 841, 10.1517/14712598.5.6.841 Hsu, 1997, Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial, Blood, 89, 3129, 10.1182/blood.V89.9.3129 Neelapu, 2005, Phase III Randomized Trial of Patient- Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report, Clin Lymphoma, 6, 61, 10.3816/CLM.2005.n.031 Timmerman, 2002, Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients, Blood, 99, 1517, 10.1182/blood.V99.5.1517 Solal-Celigny, 1998, Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial, J Clin Oncol, 16, 2332, 10.1200/JCO.1998.16.7.2332 Aviles, 2004, Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma, Leuk Lymphoma, 45, 2247, 10.1080/10428190410001723269 Smalley, 2001, Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma treated with interferon alfa (IFN- alpha2a) plus an anthracycline-based induction regimen, Leukemia, 15, 1118, 10.1038/sj.leu.2402161 Fisher, 2000, Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low- grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809, J Clin Oncol, 18, 2010, 10.1200/JCO.2000.18.10.2010 Rohatiner, 2005, Meta-analysis to evaluate the role of interferon in follicular lymphoma, J Clin Oncol, 23, 2215, 10.1200/JCO.2005.06.146 Hiddemann, 2005, Combined immuno-chemotherapy (R-CHOP) has a long lasting impact on subsequent consolidation in remission in follicular lymphoma but not in mantle cell lymphoma, Ann Oncol, 16, v111 Tse, 2004, Stem cell transplantation in follicular lymphoma: progress at last?, Bone Marrow Transplant, 34, 929, 10.1038/sj.bmt.1704654 Freedman, 1999, Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma, Blood, 94, 3325, 10.1182/blood.V94.10.3325.422k13_3325_3333 Schouten, 2003, High-dose therapy improves progression- free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial, J Clin Oncol, 21, 3918, 10.1200/JCO.2003.10.023 Voso, 2000, Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT), Bone Marrow Transplant, 25, 957, 10.1038/sj.bmt.1702336 Horning, 2001, High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial, Blood, 97, 404, 10.1182/blood.V97.2.404 Corradini, 2004, Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes, J Clin Oncol, 22, 1460, 10.1200/JCO.2004.10.054 Lenz, 2004, Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group, Blood, 104, 2667, 10.1182/blood-2004-03-0982 Lenz, 2004, Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group, J Clin Oncol, 22, 4926, 10.1200/JCO.2004.06.016 Deconinck, 2005, High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS, Blood, 105, 3817, 10.1182/blood-2004-10-3920 Sebban, 2003, Comparison of CHVP + Interferon followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: Results of the randomized GELF 94 trial, Blood, 102, 104a Gribben, 1991, Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma, N Engl J Med, 325, 1525, 10.1056/NEJM199111283252201 Fouillard, 1998, Autologous stem-cell transplantation for non-Hodgkin’s lymphomas: the role of graft purging and radiotherapy posttransplantation–results of a retrospective analysis on 120 patients autografted in a single institution, J Clin Oncol, 16, 2803, 10.1200/JCO.1998.16.8.2803 Ladetto, 2002, High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Blood, 100, 1559, 10.1182/blood-2002-02-0621 Galimberti, 2003, Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab, Bone Marrow Transplant, 32, 57, 10.1038/sj.bmt.1704102 van Besien, 2003, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 102, 3521, 10.1182/blood-2003-04-1205 Toze, 2004, Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation, Br J Haematol, 127, 311, 10.1111/j.1365-2141.2004.05194.x Peniket, 2003, An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation, Bone Marrow Transplant, 31, 667, 10.1038/sj.bmt.1703891 Khouri, 2004, Nonmyeloablative stem cell transplantation for lymphoma, Semin Oncol, 31, 22, 10.1053/j.seminoncol.2003.10.017 Marks, 2002, The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation, Blood, 100, 3108, 10.1182/blood-2002-02-0506 Mandigers, 2003, Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation, Bone Marrow Transplant, 32, 1159, 10.1038/sj.bmt.1704290 Khouri, 2001, Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality, Blood, 98, 3595, 10.1182/blood.V98.13.3595 Robinson, 2002, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, Blood, 100, 4310, 10.1182/blood-2001-11-0107 Faulkner, 2004, BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients, Blood, 103, 428, 10.1182/blood-2003-05-1406 Morris, 2004, Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non- Hodgkin lymphoma, Blood, 104, 3865, 10.1182/blood-2004-03-1105 O’Connor, 2005, Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma, J Clin Oncol, 23, 676, 10.1200/JCO.2005.02.050 O’Connor, 2005, Targeting the proteosome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience, Ann Oncol, 16, v66 Czuczman, 2005, Phase I/II study of galiximab, an anti- CD80 antibody, for relapsed or refractory follicular lymphoma, J Clin Oncol, 23, 4390, 10.1200/JCO.2005.09.018 Leonard, 2005, Results from a phase I/II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma, Ann Oncol, 16, v71 Leonard, 2003, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma, J Clin Oncol, 21, 3051, 10.1200/JCO.2003.01.082 Leonard, 2005, Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma, J Clin Oncol, 23, 5044, 10.1200/JCO.2005.13.821 Cohen, 2005, The novel alkylator bendumustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity, J Clin Oncol, 23, 576s, 10.1200/jco.2005.23.16_suppl.6564 Rummel, 2005, Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas, J Clin Oncol, 23, 576, 10.1200/jco.2005.23.16_suppl.6565 Cheson, 2004, What is new in lymphoma? CA, Cancer J Clin, 54, 260, 10.3322/canjclin.54.5.260 O’Connor, 2005, Developing new drugs for the treatment of lymphoma, Eur J Haematol Suppl, 150, 10.1111/j.1600-0609.2005.00470.x